Q-omics provides the consensus-scored ITGA1 profile across patient tissues and cancer cell-line models. ITGA1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITGA1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ITGA1 protein abundance shows 26,233 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where ITGA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA1 survival associations across molecular data types. ITGA1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA1 RNA expression–survival associations across cancer types. High ITGA1 expression shows unfavorable associations in KIRP, UVM, MESO, CESC and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITGA1 RNA expression.
This table summarizes ITGA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITGA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA1 shows lower tumor expression in THCA, LUSC, KICH and BLCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher ITGA1 RNA expression in tumor versus normal tissue (log2 FC = +2.321, t-test p < 0.001).
This table shows molecular features associated with ITGA1 in patient tissues and cancer cell lines. In patient samples, ITGA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
